A recent press release by Quest Diagnostics announced a 5-year extension to their U.S. supply agreement for the InSure® ONE™ fecal immunochemical test (FIT), a test for colorectal cancer screening programs.
Editor's Note: This article originally appeared on Quest Diagnostics' website.
Clinical Genomics, a leading innovator of tests for colorectal cancer, and Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced a 5-year extension to their U.S. supply agreement for the InSure® ONE™ fecal immunochemical test (FIT). This agreement builds upon a long standing collaboration to provide InSure FIT and the new InSure ONE FIT for colorectal cancer screening programs. Clinical Genomics manufactures FIT tests, including InSure ONE, which Quest provides to physicians and organized provider groups across the United States. These provider groups include specialized programs to improve screening adherence rates for Accountable Care Organizations (ACOs) and other organizations focused on improving quality metrics under value-based care models. Quest is also an investor in the company. Under the agreement, Quest will continue to offer broad access to both the Insure FIT and Insure ONE FIT products in the U.S. Click here to continue>>
News From Our Partners